{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-long-term-follow-up-ltfu-of-atmp-subjects”
},
“headline”: “SOP for Long-Term Follow-Up (LTFU) of ATMP Subjects”,
“description”: “This SOP outlines the standardized procedures for long-term follow-up (LTFU) of subjects in Advanced Therapy Medicinal Product (ATMP) trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements. It includes subject re-consent, monitoring, safety reporting, and data retention strategies.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Long-Term Follow-Up (LTFU) of ATMP Subjects

Purpose

The purpose of this SOP is to define standardized procedures for the long-term follow-up (LTFU) of subjects enrolled in Advanced Therapy Medicinal Product (ATMP) clinical trials. Due to the potential for delayed adverse events, gene integration risks, and long-term immunogenicity, subjects must be followed beyond the trial’s active treatment phase to ensure safety and regulatory compliance.

Scope

This SOP applies to sponsors, investigators, CROs, site staff, and regulatory affairs involved in ATMP trials. It covers subject re-consent, follow-up visits, safety reporting, data collection, data privacy, retention, regulatory submissions, and communication with subjects during extended follow-up.

Responsibilities

• Sponsor: Designs and funds LTFU programs, ensuring compliance with regional and international regulations.
• Investigator: Manages LTFU at site level, ensuring subject safety and documentation.
• CRO: Oversees monitoring and ensures adherence to LTFU requirements.
• Regulatory Affairs: Submits updates to authorities and ethics committees.
• QA: Audits LTFU records and ensures data integrity.

Accountability

The Sponsor’s Medical Director is accountable for overall LTFU compliance. The Principal Investigator is accountable for subject-level follow-up and re-consent.

Procedure

1. LTFU Planning
1.1 Develop an LTFU plan as part of the trial protocol.
1.2 Define follow-up duration (e.g., 5–25 years depending on ATMP type).
1.3 Record in LTFU Planning Log (Annexure-1).

2. Subject Re-Consent
2.1 Obtain re-consent if required by protocol or local regulations.
2.2 Document in Re-Consent Log (Annexure-2).

3. Follow-Up Visits
3.1 Schedule annual or protocol-defined follow-up visits.
3.2 Collect clinical, laboratory, and imaging data.
3.3 Document visits in Follow-Up Visit Log (Annexure-3).

4. Safety Reporting
4.1 Monitor delayed adverse events, malignancies, or gene integration effects.
4.2 Report per regulatory timelines to sponsor, EC/IRB, and regulators.
4.3 Document in LTFU Safety Log (Annexure-4).

5. Data Privacy and Retention
5.1 Ensure compliance with GDPR, HIPAA, and local privacy laws.
5.2 Retain records for minimum of 25 years for ATMPs in EU.
5.3 Record retention activities in Data Retention Log (Annexure-5).

6. Subject Communication
6.1 Provide regular updates and educational material to subjects.
6.2 Document communication in Subject Communication Log (Annexure-6).

7. Archiving
7.1 Archive all LTFU records in TMF and ISF.
7.2 Ensure accessibility for inspections and audits.

Abbreviations

• SOP: Standard Operating Procedure
• LTFU: Long-Term Follow-Up
• ATMP: Advanced Therapy Medicinal Products
• CRO: Contract Research Organization
• QA: Quality Assurance
• IRB/EC: Institutional Review Board/Ethics Committee
• GCP: Good Clinical Practice
• TMF: Trial Master File
• ISF: Investigator Site File
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act

Documents

1. LTFU Planning Log (Annexure-1)
2. Re-Consent Log (Annexure-2)
3. Follow-Up Visit Log (Annexure-3)
4. LTFU Safety Log (Annexure-4)
5. Data Retention Log (Annexure-5)
6. Subject Communication Log (Annexure-6)

References

• FDA – Long-Term Follow-Up for Cellular & Gene Therapy
• EMA – ATMP LTFU Guidelines
• CDSCO – ATMP Long-Term Monitoring
• ICH GCP – Follow-Up in ATMP Trials
• WHO – ATMP Long-Term Follow-Up Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: LTFU Planning Log

Annexure-2: Re-Consent Log

Annexure-3: Follow-Up Visit Log

Annexure-4: LTFU Safety Log

Annexure-5: Data Retention Log

Annexure-6: Subject Communication Log

Revision History

For more SOPs visit: Pharma SOP